Ellen Janssen is a Director of Benefit-Risk assessment and Epidemiology at Johnson & Johnson. She leads patient-focused benefit-risk assessments and patient preference studies to support internal decision making and health authority submissions across a variety of therapeutic areas. Ellen is passionate about ensuring that the patient voice is reflected in medical decision making. Ellen is involved as a preference expert in MDIC, BIO, and the ongoing ISPOR taskforce on preference heterogeneity. She previously participated in IMI PREFER and on the ISPOR Taskforce on using patient preferences to inform decision-making. Prior to joining J&J, Ellen led and conducted studies to measure the preferences of patients and other stakeholders. She completed her PhD training at the Johns Hopkins Bloomberg School of Public Health and has applied stated-preference methods across academic, non-profit, regulatory, and consulting settings. Her work has focused on engaging patients as research partners in preference research and the application/advancement of good research practices to ensure that patient preferences are transparently measured and accurately reflected in decision making.